Crossroads in GDNF therapy for Parkinson's disease
Identifieur interne : 001F17 ( Istex/Curation ); précédent : 001F16; suivant : 001F18Crossroads in GDNF therapy for Parkinson's disease
Auteurs : Todd B. Sherer [États-Unis] ; Brian K. Fiske [États-Unis] ; Clive N. Svendsen [États-Unis] ; Anthony E. Lang [Canada] ; J. William Langston [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-02.
English descriptors
- KwdEn :
Abstract
The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20861
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F17
Links to Exploration step
ISTEX:FBD375EF6A79165FA8441EB71DADF3B10B74AD80Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Crossroads in GDNF therapy for Parkinson's disease</title>
<author><name sortKey="Sherer, Todd B" sort="Sherer, Todd B" uniqKey="Sherer T" first="Todd B." last="Sherer">Todd B. Sherer</name>
<affiliation wicri:level="1"><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, New York</wicri:regionArea>
</affiliation>
<affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, 20 Exchange Place, Suite 3200, New York, NY 1005</mods:affiliation>
<wicri:noCountry code="subField">1005</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Fiske, Brian K" sort="Fiske, Brian K" uniqKey="Fiske B" first="Brian K." last="Fiske">Brian K. Fiske</name>
<affiliation wicri:level="1"><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Svendsen, Clive N" sort="Svendsen, Clive N" uniqKey="Svendsen C" first="Clive N." last="Svendsen">Clive N. Svendsen</name>
<affiliation wicri:level="1"><mods:affiliation>Waisman Center, University of Wisconsin, Madison, Wisconsin, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Waisman Center, University of Wisconsin, Madison, Wisconsin</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><mods:affiliation>Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Langston, J William" sort="Langston, J William" uniqKey="Langston J" first="J. William" last="Langston">J. William Langston</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Institute, Sunnyvale, California</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FBD375EF6A79165FA8441EB71DADF3B10B74AD80</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20861</idno>
<idno type="url">https://api-v5.istex.fr/document/FBD375EF6A79165FA8441EB71DADF3B10B74AD80/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F17</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F17</idno>
<idno type="wicri:Area/Istex/Curation">001F17</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Crossroads in GDNF therapy for Parkinson's disease</title>
<author><name sortKey="Sherer, Todd B" sort="Sherer, Todd B" uniqKey="Sherer T" first="Todd B." last="Sherer">Todd B. Sherer</name>
<affiliation wicri:level="1"><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, New York</wicri:regionArea>
</affiliation>
<affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, 20 Exchange Place, Suite 3200, New York, NY 1005</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Fiske, Brian K" sort="Fiske, Brian K" uniqKey="Fiske B" first="Brian K." last="Fiske">Brian K. Fiske</name>
<affiliation wicri:level="1"><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Michael J. Fox Foundation for Parkinson's Research, New York, New York</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Svendsen, Clive N" sort="Svendsen, Clive N" uniqKey="Svendsen C" first="Clive N." last="Svendsen">Clive N. Svendsen</name>
<affiliation wicri:level="1"><mods:affiliation>Waisman Center, University of Wisconsin, Madison, Wisconsin, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Waisman Center, University of Wisconsin, Madison, Wisconsin</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><mods:affiliation>Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Langston, J William" sort="Langston, J William" uniqKey="Langston J" first="J. William" last="Langston">J. William Langston</name>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Institute, Sunnyvale, California, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Institute, Sunnyvale, California</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-02">2006-02</date>
<biblScope unit="volume">21</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="136">136</biblScope>
<biblScope unit="page" to="141">141</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">FBD375EF6A79165FA8441EB71DADF3B10B74AD80</idno>
<idno type="DOI">10.1002/mds.20861</idno>
<idno type="ArticleID">MDS20861</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>GDNF</term>
<term>clinical trials</term>
<term>drug delivery</term>
<term>neuroimaging</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. © 2006 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001F17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:FBD375EF6A79165FA8441EB71DADF3B10B74AD80 |texte= Crossroads in GDNF therapy for Parkinson's disease }}
This area was generated with Dilib version V0.6.29. |